Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Six novel antimycotics.

Adam I Rubin1, Bita Bagheri, Richard K Scher

  • 1Department of Dermatology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

American Journal of Clinical Dermatology
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The National Resident Match Program Arrives in Dermatopathology: 15 Years of Resilient Advocacy by the American Society of Dermatopathology's Fellowship Training Program Directors' Committee.

Journal of cutaneous pathology·2026
Same author

Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Bowenoid Malignant Onychopapilloma.

Journal of cutaneous pathology·2026
Same author

Pregnancy Associated Atypical Onychopapilloma: A Novel Presentation of an Emerging Entity in Dermatopathology.

Journal of cutaneous pathology·2026
Same author

Characterizing Longitudinal Melanonychia in Skin of Color.

JAMA dermatology·2026
Same author

Novel Histopathologic Features of Median Canaliform Dystrophy.

Journal of cutaneous pathology·2026
Same journal

Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy.

American journal of clinical dermatology·2026
Same journal

Defining the Potential for Disease Modification in Atopic Dermatitis.

American journal of clinical dermatology·2026
Same journal

Atopic Dermatitis: New Targets and Emerging Systemic Therapies.

American journal of clinical dermatology·2026
Same journal

Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions.

American journal of clinical dermatology·2026
Same journal

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same journal

A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.

American journal of clinical dermatology·2026
See all related articles

This review covers six new antifungal agents for skin and mucosal infections. These include rilopirox, lanoconazole, NND-502, butenafine, eberconazole, and voriconazole, highlighting their potential therapeutic applications.

Area of Science:

  • Dermatology
  • Mycology
  • Infectious Diseases

Background:

  • Cutaneous and mucosal fungal infections pose significant health challenges.
  • Development of novel antimycotic agents is crucial for effective treatment.
  • Existing treatments may have limitations in efficacy or resistance profiles.

Purpose of the Study:

  • To review six emerging antimycotic agents with potential for treating human cutaneous and mucosal fungal diseases.
  • To summarize the properties, mechanisms of action, and clinical applications of these new antifungal drugs.

Main Methods:

  • Literature search of PubMed (US National Library of Medicine) for English language articles.
  • Review and synthesis of information on rilopirox, lanoconazole, NND-502, butenafine, eberconazole, and voriconazole.

Related Experiment Videos

  • Focus on pharmacological properties and reported clinical efficacy.

    • Main Results:

    • Rilopirox: A topical agent for mucosal candidiasis, tinea versicolor, and seborrheic dermatitis.
    • Lanoconazole: Topical imidazole for tinea infections, cutaneous candidiasis, with wound healing properties.
    • NND-502: Topical agent for tinea pedis, potentially more effective ergosterol inhibitor than lanoconazole.
    • Butenafine: Benzylamine derivative, approved for topical use, effective for tinea infections, with anti-inflammatory action.
    • Eberconazole: Imidazole effective against tinea infections, including some triazole-resistant yeasts.
    • Voriconazole: Oral and parenteral azole effective for oropharyngeal candidiasis and aspergillosis in immunocompromised patients.

    Conclusions:

    • The reviewed agents represent significant advancements in topical and systemic antifungal therapy.
    • These novel antimycotics offer diverse mechanisms and applications for various fungal infections.
    • Further clinical trials are warranted to fully establish the comparative efficacy and safety of these agents.